Puma Biotechnology Inc (NASDAQ: PBYI) suffers from meaningful negative changes in fundamentals: the consensus estimate for December, 2025 decreased significantly, significant quarterly earnings deceleration occurred, and the consensus estimate for December, 2026 decreased significantly.
Puma Biotechnology Inc (NASDAQ: PBYI) suffers from notable negative changes in investment behavior: its shorter term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Puma Biotechnology has a current Value Trend Rating of C (Low Neutral). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Puma Biotechnology has a neutral Appreciation Score of 53 and a slightly negative Power Rating of 37, producing the Low Neutral Value Trend Rating.
Recent Price Action
On 3/19/25, Puma Biotechnology Inc (NASDAQ: PBYI) stock enjoyed a large increase of 3.3%, closing at $3.45. However, this advance was accompanied by below average trading volume at 77% of normal. The stock has performed in line with the market over the last nine months and has risen 1.8% during the last week.
Be the first to comment